Log in

WNS Virtual Exhibit Hall


THANK YOU TO OUR EXHIBITORS AND SUPPORTERS!
Please visit the following organizations virtual exhibit booths by clicking the buttons below.

Exhibitors


AbbVie, a global, researched-based biopharmaceutical company, is committed to educating patients and caregivers about Parkinson’s disease to raise awareness about the condition, and further research to improve the lives of those living with and impacted by this disease. AbbVie is a proud sponsor of the Wisconsin Neurological Society.






Alexion is a global biopharmaceutical company with the mission of transforming the lives of people affected by rare diseases by continuously innovating and creating meaningful value in all that we do. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.



Allergan, a company of AbbVie, is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.




For the 3rd year in a row, Aspirus has been named by IBM Watson Health as one of the Nation’s Top 15 Health Systems, based on analysis of overall organizational performance and quality. We are a system of 10 hospitals and more than 50 clinics that spans over 25,000 square miles throughout Central Wisconsin and the Upper Peninsula of Michigan. Currently, over 500 providers are located throughout the system and have the opportunity to affect approximately 770,000 lives.









Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), MuSK antibody positive myasthenia gravis, and spinal muscular atrophy (SMA) type 3.

Catalyst has launched the only evidence-based, FDA-approved treatment for adult patients with Lambert-Eaton Myasthenic Syndrome (LEMS), it's the first product approved by the FDA for LEMS in more than 35 years

Coral Gables, FL | http://www.catalystpharma.com





Genentech's mission is to be the leading biotechnology company, using human genetic information to discover, develop, manufacture and commercialize medicines to treat people with serious or life-threatening medical conditions.



Gundersen Health System, based in La Crosse, WI is consistently ranked among America’s Top Hospitals for Quality and Patient Satisfaction. You will find world-class care with a small-town feel! Gundersen is a physician-led, integrated healthcare system, committed to exceptional patient and family-centered care in communities in SW Wisconsin, NE Iowa and SW Minnesota. Our 900+ clinicians practice within our 325 bed medical center as well as in 65+ regional clinics and hospital.

Be part of breakthrough advancements through innovation, research and the latest technology. As the Western Academic Campus for the University of Wisconsin School of Medicine and Public Health, our providers teach and lead research with our medical students, fellows and residents.

While you take care of others, we take care of you! Gundersen offers a competitive salary, Loan Forgiveness, substantial retirement contribution, and a generous benefits package. Enjoy the benefits of our vibrant community located along the Upper Mississippi River, where you will find abundant recreational activities, great food, the arts and excellent schools! A great place to call home.




Marshfield Clinic is part of Marshfield Clinic Health System, and is committed to enriching the lives of others through accessible, affordable compassionate healthcare. Marshfield Clinic physicians and staff serve more than 360,000 unique patients each year through accessible, high quality health care, research and education. With 700+ physicians in 86 medical specialties and subspecialties as well as over 10,000 employees in 55 clinical locations in 34 Wisconsin communities, Marshfield Clinic is nationally recognized for innovative practices and quality care.

https://www.marshfieldclinic.org/careers/physicians





Neurelis, Inc. is an innovation-driven neuroscience company providing a highly differentiated approach to target unmet medical needs. Neurelis is focused on the development and commercialization of product candidates for epilepsy and the broader central nervous system (CNS) market. We are built on a foundation of people with a passion for progress in serving the needs of people with epilepsy and those who care for them. Neurelis has reached a milestone in patient care with its first FDA-approved treatment. For further information, please visit our Product Page. For more information about Neurelis, please visit http://www.neurelis.com.




Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and commercializing life-changing treatments for people with serious, challenging and under-addressed disorders. The company's diverse portfolio includes four FDA-approved treatments as well as clinical programs in multiple therapeutic areas. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms.

For more information, visit neurocrine.com, and follow the company on LinkedIn.




Sanofi Genzyme is the specialty care global business unit of Sanofi. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com. MAT-US-2019647-v1.0-09/2020


SK life science is a subsidiary of SK biopharmaceuticals, focused on developing innovative, next-generation drugs. We have 27 years of experience in R&D and are dedicated to changing the status quo in CNS. We currently have 8 compounds in the clinical development pipeline.







Powered by Wild Apricot Membership Software